Please use this identifier to cite or link to this item:
Title: CHOP chemotherapy (ct) with rituximab and radiotherapy (RT) as a first line treatment for aggressive non-Hodgkin's lymphoma (NHL)-our experience
Authors: Simonida Crvenkova 
Aneta Dimitrovska
Vasiliki Mickovska
Issue Date: 2004
Journal: Annals of Oncology Abstract Book
Conference: 29th ESMO Congress, 2004
Abstract: Background: In advanced aggressive NHC CT is a basic treatment. Additional involved-field RT may achieve a better outcome. Aims: In this study we combined two modalities of treatment (CHOP regimen with monoclonal antibody rituximab and RT) and assessed their role. Material and Methods: We treated 40 patients (pts) with advanced aggressive NHL initially with the CHOP regimen plus rituximab. There were 26 male and 14 female, median age was 53 years (range 43-68), with stage III or IV disease. RT was given to 16 (40%) of pts. Indication for RT included initial bulky disease and lack of complete remission (CR) after CT, involved-field RT was used with one fraction per day of 1.8 Gy, to a total dose delivered by 19-22 fractions. Response was assessed at two months after the end of RT and the every three months. The primary end point was freedom from progression (FFP) and overall survival (OS) after 3 years. Median observation time was 26 months. Results: The rate of complete remission (CR) was 60% after CT. Following RT the rates of CR and PR were 81% and 19%, respectively. Three-year FFP and OS in pts who received RT were 71% and 79%, respectively. In pts who were treated with CHOP+rituximab alone 3-year FFP and OS were 52% and 61.5%, respectively. Univariant analysis showed that stage, extranodal involvement, performance status, LDH level, are significant prognostic factors for survival. Conclusion: Combination of these two modalities CT and RT showed better outcome as a first-line treatment for pts with advances aggressive NHL, the applied CT alone.
Appears in Collections:Faculty of Medicine: Conference papers

Files in This Item:
File Description SizeFormat 
JoshiAAnnalsofOncologyOct204Supplement3.pdf4.17 MBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Jan 18, 2021


checked on Jan 18, 2021

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.